Head-to-head evidence
mirikizumab vs SHR-1139
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03524092 · Phase 3 · completed
Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07232576 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mirikizumab's landscape · SHR-1139's landscape